Skip to main content

Table 2 Key findings related to tumor heterogeneity among various tumors using scRNA-seq

From: Advances in single-cell RNA sequencing and its applications in cancer research

Tumor

Year

Species

Protocol

Accession number (custom database if available)

Key findings

References

Lung cancer

2020

Human

10 × Genomics

EGAD00001005054

Identified a cancer cell subtype deviating from the normal differentiation trajectory and dominating the metastatic stage, and revealed potential diagnostic and therapeutic targets in cancer-microenvironment interactions

[156]

 

2020

Human

Smart-seq2

NCBI BioProject #PRJNA591860

Identified that individual tumors and cancer cells exhibit substantial molecular diversity and that tumor microenvironment cells exhibit marked therapy-induced plasticity

[157]

 

2022

Human

STRT-seq

HRA000270

Provided novel insights into the tumor heterogeneity of NSCLC in terms of the identification of prevalent mixed-lineage subpopulations of cancer cells with combined SCC, ADC, and NET signatures and offered clues for potential treatment strategies in these patients

[158]

Gastric cancer

2020

Human

10 × Genomics

PRJEB40416

Highlighted response heterogeneity within MSI-H gastric cancer treated with pembrolizumab monotherapy; supported the potential of extended baseline and early on-treatment biomarker analyses to identify responders

[95]

 

2021

Human

10 × Genomics

EGAS00001004443

The links between tumor cell lineage/state and ITH were illustrated at the transcriptome, genotype, molecular, and phenotype levels

[72]

 

2021

Human

10 × Genomics

HRA000051

A panel of differentiation-related genes revealed large differences in differentiation degree within and between tumors

[80]

Liver cancer

2022

Human

Seq-Well S3

GSE186975

Identified five hepatoblastoma tumor signatures that may account for the tumor heterogeneity observed in this disease, and used patient-derived hepatoblastoma spheroid cultures to predict differential responses to treatment based on the transcriptomic signature of each tumor

[237]

Esophageal cancer

2022

Human

10 × Genomics

GSE196756

Revealed intratumoral and intertumoral epithelium heterogeneity and tremendous differences between the tumor and normal epithelium. Epithelium cells and myeloid cells had more frequent cell‒cell communication than epithelium cells and T cells

[238]

 

2021

Human

10 × Genomics

PRJNA777911

Uncovered heterogeneity in most cell types of the ESCC stroma, particularly in the fibroblast and immune cell compartments

[86]

Melanoma

2016

Human

Smart-seq2

DUOS-000002; GSE72056

Malignant cells within the same tumor displayed heterogeneity in the transcription of proteins related to the cell cycle, spatial context, and drug resistance program

[239]

 

2020

Human

10 × Genomics

GSE139829

Analysis of tumor cells revealed previously unappreciated subclonal genomic complexity and transcriptional states

[94]

 

2021

Human

10 × Genomics

GSE138665

Uncovered intratumoral heterogeneity at the genome and transcriptome level

[81]

Acute lymphoblastic leukemia

2020

Human

10 × Genomics

GSE132509

The predicted developmental states of cancer cells were inversely correlated with the expression levels of ribosomal protein, which could be a common contributor to intraindividual heterogeneity in childhood ALL patients

[240]

Diffuse large B cell lymphoma

2022

Human

10 × Genomics

CNGBdb: CNP0001940

High intratumor and intertumor heterogeneity was identified in DLBCL

[216]

 

2022

Human

10 × Genomics

https://heidata.uniheidelberg.de

Provided an in-depth dissection of the transcriptional features of malignant B cells and the TME in DLBCL and new insights into DLBCL heterogeneity

[229]

Primary central nervous system lymphoma

2021

Human

10 × Genomics

GEO: GSE181304

Different subtypes of T cells and DCs showed significant heterogeneity

[85]

B-cell lymphoma

2020

Human

10 × Genomics

https://heidata.uni-heidelberg.de

Malignant subpopulations from the same patient responded strikingly differently to anticancer drugs ex vivo, highlighting the relevance of intratumor heterogeneity for personalized cancer therapy

[241]

Cutaneous T cell lymphoma

2018

Human

BD Precise assay

Correspondence with authors

Patients with SS displayed a high degree of single-cell heterogeneity within the malignant T-cell population, and the distinct subpopulation of malignant T cells exhibited HDACi resistance

[76]

 

2019

Human

10 × Genomics

GSE128531

Provided an unprecedented view of lymphocyte heterogeneity and identifying tumor-specific molecular signatures, with important implications for diagnosis and personalized disease treatment

[77]

 

2021

Human

10 × Genomics

GSE171811

Striking subclonal molecular heterogeneity was observed within clonal malignant T-cell populations in the skin and blood of patients with leukemic CTCL. The tissue microenvironment influenced the transcriptional state of malignant T cells, likely contributing to the evolution of malignant clones

[242]

 

2022

Human

10 × Genomics

GSA-Human: HRA000166

Revealed the intratumor and interlesion diversity of CTCL patients, proposed a multistep tumor evolution model that further established a novel subtype, the TCyEM group with a cytotoxic effector memory T-cell phenotype, and identified increased M2 macrophage infiltration

[78]

Subcutaneous panniculitis-like T cell lymphoma

2021

Human

10 × Genomics

GSA-Human: HRA000370

Provided insights into the heterogeneity of subcutaneous panniculitis-like T-cell lymphoma, as well as a better understanding of the transcription characteristics and immune microenvironment of this rare tumor

[208]